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ARTICLE
Cystic Fibrosis
Miss Mary Dolan
Every year members of the Royal Medical Society present dissertations 
at Private Business Meetings. Traditionally Res Medica has published 
those dissertations of wider interest. We are reintroducing this tradi­
tion with an article about cystic fibrosis which was presented last ses­
sion by one of our current presidents, Miss Mary Dolan. Please note 
that the information provided in this article, especially with respect to 
prenatal diagnosis, predates the localisation of the C.F gene.
Cystic fibrosis, a genetic disease with an 
autosomal recessive mode of inheritance, 
was first described in 1936 by Fanconi et al. 
He described the disease in a paper entitled 
The Coeliac Syndrome with congenital cys­
tic pancreatic fibromatosis and bronchieta- 
sis. Since then the disease has been known 
by various names such as Cystic Fibrosis of 
the Pancreas, Mucoviscidoses, fibrosis of 
the pancreas until it was shortened to Cystic 
Fibrosis in the 1960s.
Cystic Fibrosis represents the common­
est autosomal recessive disorder in Cauca­
sian populations. The mutant gene, recently 
identified on the long arm of chromosome 7 
has a carrier rate equal to 1 in 22 among 
Caucasians. The overall incidence of the 
disease in 1 per 2000 live births. However 
it has a much lower incidence amongst non- 
Caucasian populations. Amongst the UK 
population there are 5000 cystic fibrosis
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sufferers. Slightly more than 300 affected 
babies are bom annually.
The disease affects many tissues, espe­
cially the endocrine glands. It results in the 
production of abnormally viscous secre­
tions which cause duct obstruction and are 
therefore responsible for pancreatic insuffi­
ciency, malabsorption syndromes, biliary 
cirrhosis and male infertility. The lungs of 
cystic fibrosis patients are found to be nor­
mal at birth but are very prone to infection. 
Recurrent infection is responsible for the 
irreversible secondary lung damage which 
is usually responsible for the shortened life- 
expectancy of cystic fibrosis patients. 
Death usually results from a severe bacterial 
pneumonia or is related to the development 
of cor pulmonale from lung disease.
Clinical presentation occurs before the 
age of one year in approximately 50% of pa­
tients with recurrent respiratory infections, 
diarrhoea, rectal prolapse, failure to thrive. 
Tracheal epithelium show increased Na+ 
transport with reduced Cl* absorbance 
(Knowles 1981). Beta-stimulation of the
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Table I. Special characteristics of the salivary glands and blood cells o f cystic 
fibrosis patients
1. Decreased beta-stimulation response in salivary glands
2. ? calcium concentrations in both tissues
3. Erythrocytes: •  no active Ca2* pumps
•  low rate of passive entry of Ca2*
•  decreased Na+/K+-2C1 transporter
4. Lymphocytes and Granulocytes: decreased response to cAMP stimulation
5. Heterozygotes for the cystic fibrosis gene demonstrated an intermediate 
response (ie. greater than cystic fibrosis patients but less than normal) to 
cAMP stimulation
airway results in increased Na+ absorption 
but no change in Cl' secretion. Thus the 
signals operating via the cAMP system fail 
to increase chloride permeability. This re­
duced chloride secretion has a drying effect 
on airway surfaces.
Studies involving the salivary glands and 
erythrocytes of patients have shown several 
abnormalities (Table I). It is uncertain 
whether the viscid mucus secretion results 
from abnormal ion transport or is due to 
abnormal secretion. Uncertainties also exist 
regarding the increased respiratory infec­
tions of cystic fibrosis patients. These are 
either due to abnormal ion composition or 
mucus accumulation or both.
MANAGEMENT OF THE 
C.F. CHILD.
Current theories on the management of 
cystic fibrosis believe that early diagnosis 
and therefore earlier treatments is impor­
tant in containing the development of dis­
ease complications. Currently it is thought 
that management of a cystic fibrosis child is
improved by having the child's need coordi­
nated by one regional centre. For example 
in the Victoria state cystic fibrosis centre in 
Melbourne, 80% of children have a life 
expectancy of 20 years. (Phelani Hay 
1984). Management of the disease centres 
around pancreatic supplements, antibiotic 
therapy and physiotherapy. Vaccinations, 
especially for measles and pertussis and the 
annual influenza vaccinations are important 
for preventing the early demise of a cystic 
fibrosis child. Severe viral infections such 
as influenza or chicken pox may result in 
serious deterioration of respiratory function. 
The dose of influenza vaccine may be 
halved therefore allowing its use on chil­
dren under four years, The use of enteric- 
coated pancreatic supplements has allowed 
the normal growth and development of 
cystic fibrosis children. It has also meant 
the introduction of a normal diet for cystic 
fibrosis children. They are now advised to 
take normal calorific values of fat and an 
excess of this is the suggested managements 
of some centres. Eventually some cystic 
fibrosis children will show some signs of 
slowing of growth and weight loss. This is
5
generally associated with increased respira­
tory infection and deteriorating pulmonary 
function.
Physiotherapy on a routine daily basis 
forms an important basis for the manage­
ment of lung disease in children with cystic 
fibrosis. The aims are to clear the lungs of 
thickened mucus,irrespective of their infec­
tive status. The physiotherapy may involve 
the patients alone, a form of autogenic 
drainage. In this technique a form of con­
trolled deep breathing is supplemented by 
the use of inhalations of moisture, breathing 
against a positive expiratory pressure and 
the forced expiratory technique (huffing). 
Physiotherapy may alternatively involve a 
therapist or parents and be based on the 
manual percussion of the chest, postural 
drainage and again forced expiration by the 
patients themselves. The autogenic tech­
nique allows patients independence and 
greater flexibility. Most children with cys­
tic fibrosis comply with a physiotherapy 
routine lasting 20-30 minutes three times a 
day. Regular exercise programmes provide 
a means of coughing up secretions but must 
be a daily activity before they would substi­
tute for physiotherapy.
Continuous antibiotic therapy ins aimed 
at preventing the development of irrevers­
ible lung damage. The antibiotic regime is 
rationed by continuous monitoring of bacte­
rial pathogens in the sputum at 6 or 12 
weekly check ups. Various different organ­
isms culture the lungs at different ages in 
cystic fibrosis children. Culture of haemo- 
phillus influenza exacerbates treatment with 
amoxycillin and then Augmentin. This is 
often followed up by Staphylococcus au­
reus infection. The risk of staphylococcus 
pneumonia is much increased following a
viral infection such as measles or chicken 
pox. Fear of staphylococcal infection pre­
cipitates the use of lifelong flucloxacillin 
therapy. Further infections are with 
Pseudomonas Aeruginosa which after in­
fection cannot be eradicated. Pseudomonas 
infection can be treated aggressively by 
three monthly courses of intravenous antibi­
otics for 10-14 days in any patient in whom 
Pseudomonas cultures are positive. Train­
ing of parents and patients has facilitated the 
introduction of home intravenous antibiot­
ics. Infections and other sources of Pseudo­
monas eg. Pseudomonas Cepacea are asso­
ciated with a poor prognosis. This organism 
is resistant to antibiotic therapy and there­
fore may be responsible for further declines 
in respiratory function. One method of 
dealing with Pseudomonas cepacea has 
been to stop anti-pseudomonas therapy for 
short periods in the hope that the P. cepacae 
will be replaced by Pseudomonas aerugi­
nosa.
PRENATAL DIAGNOSIS.
The prenatal diagnosis of cystic fibrosis 
involves two techniques. Both methods are 
best suited to families with a 1 in 4 risk of 
having an infected child. Chorionic Villous 
Sampling, occurring 6-8 weeks into preg­
nancy, involves the use of restriction frag­
ments length polymorphism closely 
associated with the cystic fibrosis gene. 
Initially the cystic fibrosis affected family is 
typed first with the most favoured probe and 
enzyme. This is followed by establishing 
the phase relationships between markers 
and the cystic fibrosis gene. This usually in­
volves examining bands on southern blot of 
DNA taken from blood of both parents and 
the already affected child. If the sample 
from the affected child or the index case is
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not available for typing, then it is not pos­
sible to proceed with this form of diagnosis. 
The advantages and disadvantages of chori­
onic villous sampling is given in Table 2.
The alternative method of prenatal di­
agnosis involved the use of amniocentesis 
and the analysis of fetal microvillous en­
zymes (Glutaryl transpeptidase, aminopep- 
tidase, intestinal alkaline phosphatase). 
Amniocentesis is carried out at 16-18 weeks 
and should be reserved for those with a 1 in 
4 risk of an affected child. The advantages 
and disadvantages of aminocentesis are 
given in Table 3.
PROGNOSIS.
The long term prognosis for the disease has 
improved greatly over the last thirty years. 
The life expectancy of many children is now 
over 20 years, with approximately 25% 
reaching the age of 30 years. These im­
provements can be related to:
1. Introduction of antibiotics to treat 
severe infections and prevent a large decline 
in respiratory function related to infections.
2. Pancreatic supplements producing an 
improved diet for cystic fibrosis patients. 
These allow normal growth and improved 
quality of life for the patient. They also 
provide increased resistance to infection.
3. Early diagnosis and treatment of the 
disease can prevent the early development 
of complications eg.influenza vaccination 
prevents serious compromise of respiratory 
function due to viral infection.
4. Recognition of mild cases - ie. those 
with later diagnosis has led to improved 
survival figures.
Future hopes for the disease rest with the 
use of heart and lung transplantation for 
severe cor pulmonale; and with genetic re­
search and identifying the defective pro­
teins. Heart and lung transplantation has 
been used increasingly over the last 5 years 
as a treatment of severe cor pulmonale, a
Table II. Advantages and Disadvantages of Chorionic Villous Sampling 
Advantages
•  Increased accuracy of diagnosis.
•  Earlier diagnosis allowing a first trimester termination for all affected fetuses 
Disadvantages
•  Need for blood sample from the ‘index’ affected child
•  Requirements for early workup of nuclear family to assess theinformativeness
•  Chance that some will be uninformative or only partially informative for DNA 
probes
Greater than 5% risk of spontaneous abortion
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Table III. Advantages and Disadvantages o f amniocentesis 
Advantages
•  All pregnancies with a 1 in 4 risk of cystic fibrosis can be assessed.
•  No prior family workup is required
•  Assays may be completed within 1 hour of receipt of the sample 
Disadvantages
•  Decreased accuracy of diagnosis (cf.CVS). Increased false positives and 
false negatives
•  If termination is required then it will have to be a late termination 
(18-19 weeks).
major complication of advanced cystic fi­
brosis. Initially patients had a poor re­
sponse to transplantation but success rates 
are now improving. There have been no 
reports of the epithelial transport defects 
occurring in the new lung, although the 
defects are still present above the site of the 
anastamosis.
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The Cystic Fibrosis Gene
S.J. Louise Smith
It’s now well over a year since the cystic 
fibrosis gene was cloned and there is still 
much to be done before its localisation can 
be translated into an improvement in health 
care for affected people. I’m not going to 
go into any details on how the gene was 
located, for this information (which is 
rather technical) see ref. 1. However to put 
it rather bluntly, despite the fact that the 
gene has been localised and sequenced has 
been sequenced, no-one really knows what
it does. The cystic fibrosis gene has been 
named the CFTR gene (cystic fibrosis 
transmembrane conductance regulator). It 
is located on the long arm of chromosome 7 
and is composed of 27 extrons which code 
for 1,400 amino-acid residues. There seem 
to be several different final products of the 
CFTR gene which result from the removal 
of exons from the first nucleotide binding 
fold. The functional significance of these 
products is not known.
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